
Oncolytics Biotech Inc.
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Stock Performance (90 Days)
Layoff History
Recent News
Other Biotechnology Companies
View All →Frequently Asked Questions
Has ONCOLYTICS BIOTECH INC had layoffs?
How many employees does ONCOLYTICS BIOTECH INC have?
What industry is ONCOLYTICS BIOTECH INC in?
Is ONCOLYTICS BIOTECH INC a publicly traded company?
Where is ONCOLYTICS BIOTECH INC headquartered?
Disclaimer
Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.
This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.
Found an error? Report it here.